Proteinuric Renal Disease
2 clinical trials · Condition
◉ Watch Proteinuric Renal Disease
| Record | Firm | Date |
|---|---|---|
| Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria (NCT07224776) | Brigham and Women's Hospital | 2026-07-10 |
| A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease (NCT00469625) | Winthrop University Hospital | 2006-07-01 |
Track Proteinuric Renal Disease automatically
Every clearance here is in the API, with alerts when new ones post.